Table 1.
Pharmacological stimulation of dynamin oligomerization counteracts drug-induced alterations at the apical membrane in MDCK cells.
| Treatment | Cell height (µm) | Microvilli height (µm) | Microvilli per 9 µm2 |
|---|---|---|---|
| Control | 11 ± 2.4 | 0.63 ± 0.2 | 53 ± 13 |
| DMSO (0.2%; 30 min) | 10 ± 2.5 | 0.42 ± 0.08 | 47 ± 18 |
| Bis-T-23 (30 µM; 30 min) | 13 ± 3.2 (P < 0.001) | 0.52 ± 0.07 (P < 0.01) | 55 ± 28 (ns) |
| LatA (0.2 µM; 30 min) | 3.4 ± 2.1 (P < 0.0001) | 0.39 ± 0.09 (P < 0.001) | 28 ± 11 (P < 0.01) |
| Bis-T-23→LatA (30 min) | 10 ± 2.8 (P < 0.001)* | 0.49 ± 0.12 (P < 0.01)* | 41 ± 8 (P < 0.01)* |
| DMSO (0.1%: 24 h) | 10.2 ± 2.4 | 0.42 ± 0.01 | 52 ± 8 |
| Bis-T-23 (5 µM; 24 h) | 11.6 ± 2.5 (ns) | 0.47 ± 0.08 (ns) | 53 ± 16 (ns) |
| DMSO→Cisplatin (24 h) | 5.2 ± 2.5 (P < 0.0001) | 0.18 ± 0.05 (P < 0.0001) | 19 ± 4 (P < 0.0001) |
| Bis-T-23→Cisplatin (24 h) | 9.6 ± 4.3 (P < 0.001)* | 0.34 ± 0.09 (P < 0.001)* | 40 ± 12 (P < 0.0001)* |
For LatA experiments, MDCK cells were treated with DMSO (0.1%) or Bis-T-23 (30 µM, 0.1% DMSO) for 10 min prior to the addition of DMSO (0.1%, vehicle) or LatA (0.2 µM, 0.1% DMSO) for 20 min. In the case of cisplatin experiments, cells were treated with DMSO (0.1%) or Bis-T-23 (5 µM, 0.1% DMSO) for 1 h, after which cisplatin (35 µM) was added for an additional 23 h. The cells were subsequently processed for SEM analysis. The data represent measurements of cell height (n = 17–30 cells per condition), microvilli height (n = 33–43 microvilli per condition), and microvilli density (n = 11–14 areas per condition) in MDCK cells. Statistical significance was determined between DMSO-treated cells and LatA, Bis-T-23, or cisplatin-treated cells, or between cisplatin- or LatA-only treated cells and those that were pre-treated with Bis-T-23 (*). Statistical significance was determined using an unpaired two-tailed t-test. Error bars, mean ± S.D.